Posts by catharine

FULLY FUNDED CLINICAL STUDY OF A NOVEL THERAPY FOR THE TREATMENT OF MALADAPTIVE PAIN FOLLOWING DECLAW IN CATS

November 27th, 2018 Posted by Chronic Post-Declaw Pain, Pain Management 0 thoughts on “FULLY FUNDED CLINICAL STUDY OF A NOVEL THERAPY FOR THE TREATMENT OF MALADAPTIVE PAIN FOLLOWING DECLAW IN CATS

Trial Specifics

The purpose of this study is to evaluate the safety and analgesic effect of a novel therapy locally administered by subcutaneous nerve block injection in cats suffering from persistent and localized pain, such as that observed in some cats following onychectomy (declaw). The trial involves a one-time treatment with an investigational product administered via a subcutaneous injection around the nerves responsible the pain sensation in the front paws of declawed cats. The treatment will be administered under sedation or general anesthesia. There is no placebo in this study. An estimated 30 client-owned cats will be enrolled. Owners will be required to complete quality of life and pain surveys during the study (6 of each total). The trial site will train the owners on evaluation techniques. Trial visits include the cats’ initial consultation, treatment day (Day 0), and then recheck visits on Days 7, 14, and 28. Other medications for declaw-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study and no changes in regimen are expected in the next 4 weeks.

Trial Funding

The trial is fully funded for the full study duration (28 days). Funding includes the initial consultation, the study treatment and administration, recheck visits, required bloodwork, and management of side effects that are thought to be directly related to participation in the study.

Trial Eligibility

Trained veterinarians at the study sites will evaluate each cat for eligibility.

Cats are eligible if they meet the following inclusion criteria:

  • The cat has documented localized forelimb pain following onychectomy (declaw) surgery.
  • The cat is experiencing pain that is refractory to pain management or the owner has chosen to pursue pain management that is distinct from conventional treatment.
  • The cat has experienced a significant decrease in quality of life due to refractory pain (i.e., pain and mobility are negatively impacting quality of life).
  • Declaw procedure was performed at least 90 days before the day of RTX treatment.


Cats are not eligible if they meet any of the following exclusion criteria:

  • The cat is less than 12 months of age.
  • The cat’s body weight is less than 2 kg.
  • The cat may be unavailable for the entire study duration.
  • The cat is participating in another study.
  • The cat is pregnant or lactating.

 

This clinical trial is offered at the following location:

The Feline Medical Center
Dr. Nicole Martell-Moran
1600 Clear Lake City Blvd,
Suite B
Houston, TX 77062
Email: nicole.martell@nvanet.com
Phone: 281-480-5500

The Pet Doctor, Inc
Marcy Hammerle DVM DABVP
2301 Technology Drive
OFallon, Mo. 63303
Email: Thepetdoctorinc@gmail.com
Phone: 636-561-9122

For more information about future site locations, please contact our Clinical Trial Team: cct@animalci.com

SEEKING BLOOD SAMPLES FROM DOGS WITH HEMANGIOSARCOMA OR OSTEOSARCOMA

November 10th, 2018 Posted by Hemangiosarcoma, Oncology, Osteosarcoma 0 thoughts on “SEEKING BLOOD SAMPLES FROM DOGS WITH HEMANGIOSARCOMA OR OSTEOSARCOMA”

Project Overview

The project is focused on blood sample collection only (not treatment) for dogs with hemangiosarcoma or osteosarcoma. Dogs with a suspicious diagnosis of hemangiosarcoma or osteosarcoma will have a single blood sample collected prior to surgery. No therapy targeted at the treatment of these cancers is permitted prior to the blood sample collection. Following surgery, dogs are permitted to receive treatment at the discretion of the veterinarian and dog owner.

Project Eligibility

Trained veterinarians at the trial sites will evaluate each dog based on eligibility parameters listed below:

  • Suspicious diagnosis of hemangiosarcoma or osteosarcoma (any anatomical location)
  • Any breed, sex, age
  • Gross disease must be present at the time of blood sample collection
  • Owner must sign a consent form prior to blood sample collection
  • No prior therapy for hemangiosarcoma or osteosarcoma
  • Surgery must be performed and histopathology report obtained

 

Project Funding

The project pays for the blood sample collection and submitting the histopathology report following collection of the sample. No direct owner incentive is provided.

SEEKING DOGS FOR ENROLLMENT IN A CLINICAL TRIAL EVALUATING A NOVEL THERAPY FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA

October 2nd, 2018 Posted by Bladder Cancer, Pain Management 0 thoughts on “SEEKING DOGS FOR ENROLLMENT IN A CLINICAL TRIAL EVALUATING A NOVEL THERAPY FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA”

Trial Specifics

This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC). The trial involves one-time treatment administered directly into the bladder using a urinary catheter. Dogs may receive a second treatment one month after enrollment if warranted. The treatment will be administered under sedation or general anesthesia. There is no placebo in this trial. An estimated 15 client-owned dogs with will be enrolled. Owners will be required to complete quality of life surveys, collect a daily urine sample for visual analysis, and record the urine collection results in a provided journal. The trial site will train the owners on collection and evaluation techniques. Trial visits include the dog’s initial consultation, treatment day (Day 0), and then recheck visits on Days 7, 14, 28, 56, and 84. Anti-cancer therapies must be discontinued 21 days prior to enrollment. Medications targeted at the treatment of TCC-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.

Trial Funding

The trial is fully funded for the full trial duration (84 days). Funding includes the initial consultation, the study treatment and administration, thoracic radiographs at the beginning and end of the study, monthly abdominal ultrasounds, recheck visits, trial-required bloodwork, and management of side effects that are thought to be directly related to the trial.

Trial Eligibility

Trained veterinarians at the trial sites will evaluate each dog for eligibility.

Dogs are eligible if they meet the following inclusion criteria:

  • Dog presenting with a diagnosis of TCC exclusively associated with the bladder (metastasis is acceptable).
  • Dog with accompanying lower urinary tract clinical signs associated with bladder cancer.
  • Bladder lesion does not prevent the passage of urinary catheter.


Dogs are not eligible if they meet any of the following exclusion criteria:

  • Dog with urethral or prostatic involvement of TCC.
  • Dog has any underlying disease that will affect the study objectives or patient safety.
  • Dog has evidence of hydronephrosis.
  • Dog has an active urinary tract infection (dogs presenting for screening will have a urine culture performed prior to enrollment).
  • Dog has a urethral obstruction.
  • Dog is pregnant or lactating.
  • Dog is participating in another study.

 

This clinical trial is offered at the following locations:

Hope Veterinary Specialists
40 Three Tun Road
Malvern, PA 19355
610-296-2099

Las Vegas Veterinary Specialty Center
8650 W. Tropicana Avenue, Ste. B-107
Las Vegas, NV 89147
702-871-1152

BluePearl Specialty and Emergency
11950 West 110th St
Overland Park, KS 66210
913-642-9563

The Oncology Service – Dogwood
5918 West Broad St
Richmond, VA 23230
804-716-4710

The Veterinary Cancer Center
129 Glover Ave, Norwalk
Norwalk, CT 06850
203-838-6626

A STOOL SAMPLE COLLECTION STUDY TO DEVELOP A DIAGNOSTIC TOOL FOR DISTINGUISHING GASTROINTESTINAL LYMPHOMA FROM INFLAMMATORY BOWEL DISEASE IN CATS

April 25th, 2018 Posted by Lymphoma, Oncology 0 thoughts on “A STOOL SAMPLE COLLECTION STUDY TO DEVELOP A DIAGNOSTIC TOOL FOR DISTINGUISHING GASTROINTESTINAL LYMPHOMA FROM INFLAMMATORY BOWEL DISEASE IN CATS”

Study Overview

The study seeks to identify 50 cats that have a confirmed diagnosis of IBD or GI lymphoma (endoscopy/colonoscopy, surgery with biopsies or ultrasound guided FNA that confirms large cell lymphoma). Stool samples will then be collected from these cats. Tumor samples may ultimately be collected from cats undergoing surgical biopsies and formalin fixed. All cats that are eligible for the study will require pretreatment stool samples, a demographic sheet that will be filled out by the pet owner determining the age, breed, medications, etc., and a clinical report that will be filled out by the treating veterinarian that provides the disease diagnosis. Logistics associated with collection are as followed:

Study Eligibility

Trained veterinarians at the trial sites will evaluate each cat for eligibility.

Cats are eligible if they meet the following inclusion criteria:

  • Cat has undergone a procedure (endoscopy, colonoscopy, laparotomy or ultrasound-guided FNA) for a diagnosis of IBD or GI lymphoma. FNA will only be accepted for those cats that have a diagnosis of large cell lymphoma
  • Cat has a confirmed diagnosis of IBD or GI lymphoma
  • Owner understands and signs informed consent
  • Stool sample collected prior to treatment for IBD or GI lymphoma


Cats are not eligible if they meet any of the following exclusion criteria

  • Cats diagnosed with any other cancer
  • Cats receiving anti-inflammatory or immunosuppressive therapy
  • Cats, that within the last 3 months, have had a positive fecal examination for parasitic, bacterial, or viral infection.


Study Funding

For a cat enrolled in the study to be considered complete, the stool sample and demographic data must be received by Sponsor and the site must have filled-out all clinical data on the online interface. The Sponsor will reimburse the pet owner by mailing him or her a gift card and ACI will reimburse the site for every 5 completed cases or at the end of the study.
This study is offered at the following locations:

Friendship Hospital for Animals
4105 Brandywine St. NW
Washington, DC 20016
202.363.7300

Care Veterinary Center
1080 W. Patrick St.
Frederick, MD 21703
301.662.2273

Veterinary Specialty Hospital – San Diego
10435 Sorrento Valley Rd.
San Diego, CA 92121
868.875.7500

Veterinary Specialty Hospital – North County
2055 Montiel Rd. #104
San Marcos, CA 92069
760.466.0600

Premier Chicago
3927 W. Belmont Ave.
Chicago, IL 60618
773.516.5800

Premier Crestwood
13715 S. Cicero Ave.
Crestwood, IL 60418
708.388.3771

Premier Grayslake
1810 E. Belvidere Rd.
Grayslake, IL 60030
847.548.5300

Boston West Veterinary Emergency and Specialty
5 Strathmore Road
Natick, MA 01760
508.319.2117

The Life Centre
165 Fort Evans Rd NE
Leesburg, VA 20176
703.777.5755

BluePearl – Southfield, MI
29080 Inkster Road
Southfield, MI 48034
248.354.6640

A FUNDED CLINICAL TRIAL TO EVALUATE A NOVEL PAIN MANAGEMENT THERAPY IN DOGS WITH SEVERE ELBOW DYSPLASIA

January 25th, 2018 Posted by Osteoarthritis, Pain Management 0 thoughts on “A FUNDED CLINICAL TRIAL TO EVALUATE A NOVEL PAIN MANAGEMENT THERAPY IN DOGS WITH SEVERE ELBOW DYSPLASIA”

Trial Specifics

This trial is designed to evaluate the tolerability, safety and effectiveness of a novel pain management therapy in dogs with severe elbow dysplasia with osteoarthritis. The drug is administered as one-time intra-articular injections into both elbows in most dogs. The injection will be administered under sedation or general anesthesia. There is no placebo in this trial. An estimated 28 client-owned dogs with will be enrolled. Owners will be required to complete pain assessment surveys, track their dog’s activity through the use of an activity monitor worn on the dog’s collar, and record short at-home videos assessing the dog’s gait. The trial site will train the owners on all of these assessments. Trial visits include the dog’s initial consultation, treatment day (Day 0), and then recheck visits on Days 14, 28, 56, and 84. Medications targeted at the treatment of osteoarthritis/ elbow dysplasia associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.

Trial Funding

The trial is fully funded for the full trial duration (84 days). Funding includes the initial consultation, the study treatment and administration, radiographs prior to treatment (if not performed within 4 months of enrollment), recheck visits, required bloodwork, and management of side effects that are thought to be directly related to the trial.

Trial Eligibility

Trained veterinarians at the trial sites will evaluate each dog for eligibility.

Dogs are eligible if they meet the following inclusion criteria:

  • Dog’s body weight 10-50 kg
  • Dog has clinical signs and radiographic evidence of elbow dysplasia
  • Dog is experiencing elbow-associated pain that is refractory to standard pain management or owner opts for pain management that is distinct from conventional treatments


Dogs are not eligible if they meet any of the following exclusion criteria:

  • Dog has a life expectancy of < 3 months
  • Dog has any underlying disease that will affect the study objectives or patient safety
  • Dog has concurrent or prior immune-mediated or other disease resulting polyarthropathy
  • Dog is impaired due to neurological disease or other orthopedic disease
  • Dog is pregnant or lactating
  • Dog is participating in another study
  • Dog may be unavailable for the entire trial duration or is felt to be unsuitable by the investigator for any other reason
  • Dog requires medications or supplements during the course of the study that interfere with the objectives of the study including but not limited to TRPV1 agonist or antagonist drugs that could interfere with RTX mode of action (such as cannabinoids like CBD and anandamide)

 

This clinical trial is offered at the following locations:

Peak Performance Veterinary Group
700 Summit Blvd.
Frisco, CO 80443
970-233-0795

Veterinary Specialty and Emergency Center
625 Ridge Pike, Building B
Conshohocken, PA 19428
484-567-7999

Animal Surgical Clinic of Seattle
14810 15th Ave. NE
Shoreline, WA 98155
206-545-4322

Quakertown Veterinary Clinic
2250 N. Old Bethlehem Pike
Quakertown, PA 18951
215-536-6245

Colorado Canine Orthopedics
5528 N. Nevada Ave.
Colorado Springs, CO 80918
719-264-6666

Boston West Veterinary Emergency and Specialty
5 Strathmore Rd
Natick, MA 01760
508-319-2117